RasGAP derived peptide for selectively killing cancer cells
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Feb 7, 2012
Grant Date -
Oct 19, 2006
app pub date -
Jun 30, 2004
filing date -
Jun 30, 2003
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
The present invention relates to a peptide consisting in the N2 sequence of the RasGAP protein, a fragment thereof, or a variant thereof which enhances the ability of a drug to selectively kill cells. Furthermore, it relates to a pharmaceutical composition comprising as an active substance a pharmaceutically effective amount of the peptide.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully